Peter Grant Miller

Distinct Proteasomal Pathways Drive Oncogenic PPM1D Activation

This study shows that truncating mutations in PPM1D shift its degradation pathway from ubiquitin-independent to UBR5-mediated, leading to increased PPM1D levels and oncogenic effects.

Clonal Hematopoiesis Instructs Maladaptive Tissue Repair to Promote Fibrosis

This study shows clonal hematopoiesis promotes fibrosis by altering macrophage behavior and tissue repair processes in lung disease.

BIRC5 dependency defines a targetable vulnerability in TP53 mutant acute myeloid leukemia

This study identifies BIRC5 as a targetable vulnerability in TP53 mutant AML, showing that survivin/IAP inhibitors can overcome therapy resistance.

Identification of Small Molecule Inhibitors of PPM1D Using a Novel Drug Discovery Platform

This study identifies new PPM1D inhibitors using a drug discovery platform and shows their distinct biological effects compared to other DDR and p53 pathway modulators.

Somatic mutations in chronic lung disease are associated with reduced lung function

The paper finds that somatic mutations in diseased lung tissue correlate with reduced lung function and cell type proportions in COPD and IPF.